載入...
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
Graft-versus-host disease (GVHD) is a significant complication of allogeneic stem cell transplantation (alloSCT). The proteasome inhibitor bortezomib has immunomodulatory properties of potential benefit for GVHD control. We undertook a phase 1 trial of bortezomib, tacrolimus, and methotrexate for GV...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2925723/ https://ncbi.nlm.nih.gov/pubmed/19713456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-231092 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|